RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Acceleron Pharma Stock

Acceleron Pharma ROCE 2025

Acceleron Pharma ROCE

0

Ticker

XLRN

ISIN

US00434H1086

WKN

A1W5LE

In 2025, Acceleron Pharma's return on capital employed (ROCE) was 0, a 0% increase from the 0 ROCE in the previous year.

Acceleron Pharma Aktienanalyse

What does Acceleron Pharma do?

Acceleron Pharma Inc. is a biopharmaceutical company based in Cambridge, Massachusetts. It was founded in 2003 by a group of scientists specializing in drug development in the fields of oncology and hematology. The company's business model is based on the discovery and development of innovative therapeutic solutions, particularly in the areas of oncology and rare diseases. They use a wide range of technologies to identify potential target molecules and test their effectiveness. Acceleron Pharma operates in three different business areas: oncology, hemoglobinopathies, and musculoskeletal diseases. In oncology, the company focuses on developing drugs to treat cancers such as multiple myeloma or pancreatic cancer. The hemoglobinopathies division of Acceleron Pharma develops therapies for patients with rare blood disorders such as beta-thalassemia and sickle cell disease. In the field of musculoskeletal diseases, the company is working on developing therapies for muscle, connective tissue, and joint disorders. One of Acceleron Pharma's key products is the drug Reblozyl, which was developed in collaboration with Bristol Myers Squibb. Reblozyl is the first FDA-approved medication for the treatment of anemia in patients with beta-thalassemia. The company has also entered into a partnership agreement with Celgene to develop medications for the treatment of inflammatory bowel diseases. Acceleron Pharma has also successfully partnered with other major pharmaceutical companies such as Pfizer and Sanofi in the past. Through these partnerships, the company has provided its technology platform for the discovery and development of drugs for various indications such as cancer and muscle diseases. Acceleron Pharma is a fast-growing company dedicated to researching and developing innovative therapies for rare diseases. With a wide range of technologies and a strong pipeline of clinical candidates, the company is well-equipped to treat patients affected by these rare diseases. Acceleron Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Acceleron Pharma's Return on Capital Employed (ROCE)

Acceleron Pharma's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Acceleron Pharma's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Acceleron Pharma's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Acceleron Pharma’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Acceleron Pharma stock

What is the ROCE (Return on Capital Employed) of Acceleron Pharma this year?

The ROCE of Acceleron Pharma is 0 undefined this year.

How has the ROCE (Return on Capital Employed) of Acceleron Pharma developed compared to the previous year?

The ROCE of Acceleron Pharma has increased by 0% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Acceleron Pharma?

A high Return on Capital Employed (ROCE) indicates that Acceleron Pharma has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Acceleron Pharma?

A low ROCE (Return on Capital Employed) can indicate that Acceleron Pharma has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Acceleron Pharma impact the company?

An increase in the ROCE of Acceleron Pharma can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Acceleron Pharma affect the company?

A decrease in ROCE of Acceleron Pharma can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Acceleron Pharma?

Some factors that can affect Acceleron Pharma's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Acceleron Pharma so important for investors?

The ROCE of Acceleron Pharma is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Acceleron Pharma take to improve the ROCE?

To improve the ROCE, Acceleron Pharma can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Acceleron Pharma pay?

Over the past 12 months, Acceleron Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Acceleron Pharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Acceleron Pharma?

The current dividend yield of Acceleron Pharma is .

When does Acceleron Pharma pay dividends?

Acceleron Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Acceleron Pharma?

Acceleron Pharma paid dividends every year for the past 0 years.

What is the dividend of Acceleron Pharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Acceleron Pharma located?

Acceleron Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Acceleron Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Acceleron Pharma from 10/21/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/21/2025.

When did Acceleron Pharma pay the last dividend?

The last dividend was paid out on 10/21/2025.

What was the dividend of Acceleron Pharma in the year 2024?

In the year 2024, Acceleron Pharma distributed 0 USD as dividends.

In which currency does Acceleron Pharma pay out the dividend?

The dividends of Acceleron Pharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Acceleron Pharma stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Acceleron Pharma

Our stock analysis for Acceleron Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Acceleron Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.